Abstract
Objective:Effects of drugs or immunotherapy on the quality of life of adult patients with allergic rhinitis（AR） were assessed using the rhinoconjunctivitis quality of life questionnaire（RQLQ）. Method:A total of 142 patients were included, including 37 patients receiving specific immunotherapy（SIT）（SIT group）. The remaining 105 patients received standardized drug treatment, and were divided into 87 cases in the receiving drug application instruction group（A1 group） and 18 cases in the non-receiving drug application instruction group（A2 group） according to whether or not receiving the drug application guidance group. According to whether or not receiving supervision of drug applications, they were divided into 33 cases of receiving drug application supervision group（B1 group） and 72 cases of non-receiving drug application supervision group（B2 group）. Using telephone follow-up, RQLQ was used to evaluate the patients 'daily activities, sleep, non-nasal-eye symptoms, nasal symptoms, eye symptoms, practical problems, and emotional 7 major directions, a total of 28 small surveys. Research data was analyzed and processed by SPSS 17.0 software. Result:The higher the education level, the higher the quality of life score of patients with allergic rhinitis（P<0.05）. There was no statistically significant effect of gender on psychomotor disorder in AR patients（P>0.05）. Immunotherapy improved nasal and ocular symptoms and possess statistical significance（P<0.01）. The improvement of nasal symptoms was more pronounced in SIT group and A1 group（P<0.05）. The quality of life of A1 group and B1 group improved significantly after treatment（P<0.01）. After treatment, A1 group had a significant improvement in quality of life compared to A2 group（P<0.01 or P<0.05）; The B1 group had a significant improvement in the quality of life compared to the B2 group（P<0.05 or P<0.01）. Conclusion:Life quality of AR patients can be improved to a certain extent, with simple drug therapy or immunotherapy, and SIT is more effective than drug therapy. The quality of life of AR patients can be improved by improving medication guidance and publicity.